↓ Skip to main content

Dove Medical Press

Article Metrics

Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, July 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
32 Mendeley
Title
Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study
Published in
International Journal of Chronic Obstructive Pulmonary Disease, July 2017
DOI 10.2147/copd.s137659
Pubmed ID
Authors

Dave Singh, Mario Scuri, Sara Collarini, Stefano Vezzoli, Fabrizia Mariotti, Annamaria Muraro, Daniela Acerbi

Abstract

An extrafine formulation of the long-acting muscarinic antagonist glycopyrronium bromide (GB) is in development for chronic obstructive pulmonary disease (COPD), in combination with beclometasone dipropionate and formoterol fumarate - a "fixed triple". This two-part study was randomized, double blind, placebo controlled in patients with moderate-to-severe COPD: Part 1: single-dose escalation, GB 12.5, 25, 50, 100 or 200 μg versus placebo; Part 2: repeat-dose (7-day), four-period crossover, GB 12.5, 25 or 50 μg twice daily (BID) versus placebo, with an open-label extension in which all patients received tiotropium 18 μg once daily. On the morning of Day 8 in all five periods, patients also received formoterol 12 μg. In study Part 1, 27 patients were recruited. All GB doses significantly increased from baseline forced expiratory volume in 1 second (FEV1) area under the curve (AUC0-12h) and peak FEV1, with a trend toward greater efficacy with higher GB dose. All adverse events were mild-moderate in severity, with a lower incidence with GB than placebo and no evidence of a dose-response relationship. In study Part 2, of 38 patients recruited, 34 completed the study. Adjusted mean differences from placebo in 12 h trough FEV1 on Day 7 (primary) were 115, 142 and 136 mL for GB 12.5, 25 and 50 μg BID, respectively (all P<0.001). GB 25 and 50 μg BID were superior (P<0.05) to GB 12.5 μg BID for pre-dose morning FEV1 on Day 8. For this endpoint, GB 25 and 50 μg BID were also superior to tiotropium. Compared with Day 7, addition of formoterol significantly increased Day 8 FEV1 peak and AUC0-12h with all GB doses and placebo (all P<0.001). All adverse events were mild-moderate in severity and there was no indication of a dose-related relationship. This study provides initial evidence on bronchodilation, safety and pharmacokinetics of extrafine GB BID. Overall, the results suggest that GB 25 μg BID is the optimal dose in patients with COPD.

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 22%
Other 6 19%
Student > Bachelor 4 13%
Researcher 3 9%
Student > Ph. D. Student 2 6%
Other 1 3%
Unknown 9 28%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 8 25%
Medicine and Dentistry 5 16%
Biochemistry, Genetics and Molecular Biology 2 6%
Psychology 2 6%
Nursing and Health Professions 1 3%
Other 3 9%
Unknown 11 34%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 July 2017.
All research outputs
#1,678,117
of 11,435,137 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#214
of 1,326 outputs
Outputs of similar age
#58,013
of 262,023 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#13
of 58 outputs
Altmetric has tracked 11,435,137 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,326 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,023 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.